Aktis Oncology (AKTS) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MoonLake Immunotherapeutics is the larger company by market cap ($942.1 million vs $901.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | MLTX |
|---|---|---|
| Share price | $16.15 | $11.07 |
| Market cap | $901.14M | $942.13M |
| 1-day change | -1.52% | +0.36% |
| YTD return | — | -16.01% |
| 1-year return | — | -12.63% |
| 5-year return | — | +12.16% |
| EPS (TTM) | $-1.80 | $-3.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-227.32M |
| 52-week high | $34.19 | $23.29 |
| 52-week low | $13.96 | $9.46 |
| Distance from 52-week high | -52.76% | -52.47% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +122.17% | +173.62% |
| Average volume | 408.46K | 1.64M |
| Shares outstanding | 53.93M | 85.11M |
| Employees | 79 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
AKTS vs MLTX FAQ
Which is bigger, Aktis Oncology or MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) is larger, with a market capitalization of $942.13M compared with $901.14M for Aktis Oncology (AKTS).
Are Aktis Oncology and MoonLake Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.